Valuation: Genexine, Inc.

Market Cap 243B 163M 143M 132M 121M 229M 15.73B 234M 1.57B 619M 7.7B 613M 600M 26.52B P/E 2022
-8.34x
P/E 2023 -5.99x
Enterprise Value 246B 165M 144M 133M 123M 232M 15.92B 237M 1.59B 627M 7.8B 621M 607M 26.84B EV / Sales 2022
33x
EV / Sales 2023 93.4x
Free-Float
86.57%
Yield 2022 *
-
Yield 2023 -
04-28 Genexine Inc Demonstrates First-In-Class Sox2 Degrader Gx-Bp1 in Preclinical Models CI
03-16 Egret Therapeutics, Inc and Genexine, Inc Sign Memorandum Of Understanding For Asset Transfer Of GX-P1 (EGT-101) CI
03-16 Egret Therapeutics Inc. signed a non-binding Memorandum of Understanding to acquire full right, title, and interest in lead asset EGT-101 (GX-P1) from Genexine, Inc.. CI
01/10/25 Genexine, Inc. announced that it has received KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
23/09/25 Genexine, Inc. announced that it expects to receive KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
07/03/25 Boehringer Ingelheim Ends Development of Steatohepatitis Drug, Returns Rights to Yuhan MT
01/10/24 Genexine, Inc. completed the acquisition of EPD Biotherapeutics Inc. CI
04/07/24 Genexine, Inc. Appoints Jaehyun Choi as Head of R&D CI
26/06/24 Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion. CI
14/05/24 Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
14/11/23 Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23/10/23 Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority CI
31/08/23 Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday MT
1 day+1.08%
1 week-2.69%
Current month-6.93%
1 month-26.45%
3 months-66.90%
6 months-46.22%
Current year-49.84%
1 week 2,140
Extreme 2140
2,460
1 month 2,140
Extreme 2140
2,900
Current year 2,140
Extreme 2140
7,490
1 year 2,140
Extreme 2140
7,490
3 years 2,140
Extreme 2140
12,300
5 years 2,140
Extreme 2140
73,692.31
10 years 2,140
Extreme 2140
146,384.62
Manager TitleAgeSince
Chief Executive Officer 51 26/03/2025
Chief Executive Officer 61 27/01/2023
Corporate Officer/Principal 49 01/01/2022
Director TitleAgeSince
Chairman 68 -
Director/Board Member 74 29/03/2022
Director/Board Member 61 27/01/2023
Date Insider Type Main position Quantity % Market Cap.
10/22/24 A Others 563,723 1.3580%
10/22/24 A Others 156,632 0.3773%
10/22/24 A Others

Chief Executive Officer

1,691,165 4.0741%
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%-2.69%-64.34%-75.67% 71.87M
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.39%-2.63%+30.26%+157.85% 23.36B
Weighted average by Cap. -2.80%-2.36%+40.09%+144.04%

Financials

2022 2023
Net sales 16.14B 10.85M 9.48M 8.75M 8.07M 15.21M 1.05B 15.54M 105M 41.15M 512M 40.76M 39.87M 1.76B 4.43B 2.98M 2.6M 2.4M 2.21M 4.17M 287M 4.26M 28.69M 11.29M 140M 11.18M 10.93M 483M
Net income -55.97B -37.64M -32.9M -30.36M -27.98M -52.74M -3.62B -53.91M -363M -143M -1.78B -141M -138M -6.11B -66.87B -44.97M -39.3M -36.27M -33.43M -63.01M -4.33B -64.4M -433M -170M -2.12B -169M -165M -7.3B
Net Debt 62.14B 41.79M 36.52M 33.7M 31.06M 58.55M 4.02B 59.85M 403M 158M 1.97B 157M 153M 6.79B 2.94B 1.98M 1.73M 1.6M 1.47M 2.77M 191M 2.84M 19.09M 7.51M 93.41M 7.44M 7.27M 322M
Logo Genexine, Inc.
Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
Employees
86
Date Price Change Volume
16/07/26 ₩2,350.00 +1.08% 101,088
15/07/26 ₩2,325.00 +5.92% 87,531
14/07/26 ₩2,195.00 -3.52% 130,664
13/07/26 ₩2,275.00 -5.80% 109,929
10/07/26 ₩2,415.00 +4.55% 64,974
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A095700 Stock